Clarification of pathogenesis in patients with dermatomyositis and rapidly progressive interstitial lung disease for new therapeutic approach

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09534
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Collagenous pathology/Allergology
• Research Institution: Tokai University
• Principal Investigator: SATO Shinji 東海大学, 医学部, 教授 (90276238)
• Co-Investigator(Renkei-kenkyūsha): SASAKI Noriko 東海大学, 医学部, 助教 (50734406)
• Research Collaborator: NOGI Shinichi 東海大学, 医学部付属病院, 非常勤医師
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 抗MDA5抗体 / 皮膚筋炎 / 急速進行性間質性肺炎 / 抗体価 / 予後予測 / 再発予測

Outline of Final Research Achievements

Dermatomyositis (DM) is sometimes accompanied by rapidly progressive interstitial lung disease (RP-ILD) especially in patients with clinically amyopathic dermatomyositis (CADM), a clinical subtype of DM. It is known that RP-ILD with DM has a very poor prognosis despite of intensive treatment with high-dose corticosteroid and immunosuppressive agents. Anti-CADM-140/MDA5 (Melanoma Differentiation-Associated Gene 5) antibody (anti-MDA5 antibody) is one of DM-specific autoantibodies and is well known by its close association with RP-ILD. In this study, it was suspected that IL-6 might be involved in the pathogenesis of DM and RP-ILD according to the results of cytokine profile. Our findings also highlight the usefulness of this antibody not only in the prediction of RP-ILD but also in monitoring of the disease activity and prediction of disease outcome both in short-term and long-term follow up.

Free Research Field

医歯薬学